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INTRODUCTION
1INTRODUCTION
The Most common cause of Mitral stenosis  in developing countries like
india is rheumatic fever,[19] with rheumatic manifestations present in
almost  99% of mitral stenosis patients.  25% of RHD patients have
isolated MS, and 40% have combined MS and MR.
 Involvement of multivalve is seen in 38% patients, in about 35% have
aortic valve and the tricuspid valve in about 6%. Rarely pulmonic valve
is affected.
In acute rheumatic fever, there is inflammation and edema of the
leaflets, with small fibrin-platelet thrombi along the leaflet contact
zones. Subsequently patients develop scarring leads to the characteristic
valve deformity, with obliteration of the normal leaflet architecture by
fibrosis, neovascularization and increased collagen and tissue
cellularity.
Almost Two thirds patients with rheumatic MS are female. The onset of
rheumatic fever and clinical evidence of MV obstruction is variable,
ranging from a few years to more than 20 years.[ .[20]
In developing countries- like india mitral stenosis progresses much more
rapidly, because of more severe or repeated streptococcal infections,
2genetic influences, or economic conditions, and may lead to symptoms
in the late teens and early twenties.
Asymptomatic or minimally symptomatic patients 10 years Survival is
>80%   without treatment.
Once patients develop symptoms (Functional Class III/IV) , survival
without treatment  predictably worsens and has been around at 0–15%
over the subsequent 10 years.
Mortality rate of patients with mitral stenosis without treatment is
attributable to progressive heart failure in 60– 70% of patients,
systemic embolism in 20–30%, pulmonary embolism in 10%, and
infection in 1–5%.
Initial presentation of patients with  mild and moderate mitral stenosis
(MVO  1.5  to  2.0  cm2) may be due to exercise , fever, pregnancy,
emotional upset or atrial fibrillation, especially with a rapid ventricular
response which precipitate the symptoms.
In these patients Percutaneous  Transvenous mitral Commissurotomy
helpful to avoid early surgery.
3PTMC  is the procedure of choice for the MS patients so that surgical
treatment is now reserved for patients who require treatment and valve
morphology not suitable for a percutaneous procedure.
Various invasive catheterisation studies confirmed reduction in
pulmonary artery parameters After PTMC. In our study we used non
invasive echocardiographic parameters to confirm the reduction in
pulmonary artery parameters and how much extent theses parameters
decreased after the procedure.
 We also studied, is there reduction of pulmonary artery parameters after
the onset of mitral regurgitation as a complication of PTMC procedure.
AIMS  AND OBJECTIVES
4AIMS AND OBJECTIVES
To analyze Pulmonary Artery Parameters before and after Successful
PTMC, in Rheumatic Mitral Stenosis patients by  Echocardiography.
INCLUSION CRITERIA
Patients with isolated moderate and severe rheumatic MS who are
candidates for intervention in the form of NYHA class ?II, planimetry
MVA  <1.5  cm2 and echocardiographic favorability for PTMC in the
form of mitral regurgitation ? II/IV and suitable valve morphology were
included.
All patients undergoing successful PTMC in Rheumatic Mitral stenosis
with suitable criteria between  July  2013 and March 2014 in the
department of Cardiology, RGGGH, Chennai were included in the
study.
EXCLUSION CRITERIA
Patients with Systemic hypertension, Diabetes mellitus, More than mild
mitral or aortic regurgitation and/or aortic stenosis or with any other
heart muscle diseases were excluded.
Unsuccessful PTMC cases and patients with RV dysfunction as well as
Patients who were unwilling to give consent for the study were
excluded.
 REVIEW  OF  LITERATURE
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Mitral stenosis
Mitral stenosis is characterized by  inflow obstruction of left ventricle
at the level of mitral valve due to abnormality of the mitral valve
apparatus. Rheumatic fever is the  most common cause of mitral
stenosis . Other rare etiologies include congenital mitral stenosis,
rheumatoid arthritis , carcinoid disease, SLE , Fabry disease
,mucopolysaccharidoses of the Hunter-Hurler phenotype, methysergide
therapy  and Whipple disease.
Diagnostic features of rheumatic mitral stenosis is   leaflet thickening at
the  edges, fusion of the commissures, and chordal shortening .
With acute rheumatic fever, there is inflammation and edema of the
leaflets, with small fibrin-platelet thrombi along the leaflet contact
zones. Subsequent occurrence of scarring leads to the characteristic
valve deformity, with obliteration of the normal  architecture of leaflet
by fibrosis, neovascularization and increased collagen and tissue
cellularity.
In initial stages of the disease, the relatively flexible leaflets snap open
in diastole into a curved shape because of restriction of motion at the
6leaflet tips. This diastolic doming is more evident in the motion of the
anterior leaflet.  Becomes less prominent as the affected leaflets become
more fibrotic and calcified.
{Parasternal long-axis (left) and short-axis (right) 2D
echocardiographic views showing the characteristic findings in
rheumatic  MS. Note the commissural fusion that results in doming of
the leaflets in the Parasternal long-axis view and in a decrease in the
width of the MVO in the short-axis view}
The symmetrical fusion of the commissures results in a  central small
oval orifice in diastole.  In autopsy specimens is shaped like a fish
mouth or buttonhole because the anterior leaflet is not in the
physiological open position.
7Recurrent infection as an important determinant in disease progression.
Restenosis after mitral valvuloplasty is caused by fibrosis and leaflet
thickening  rather than recurrent commissural fusion.
Pathophysiology
The  useful descriptor of the severity of mitral valve obstruction is
mitral valve orifice area in diastole. In normal adults, mitral valve
orifice area is 4 to 6 cm2. When the orifice is reduced to approximately
2 cm2, which is considered to represent mild MS, blood can flow from
the left atrium to the left ventricle only if propelled by a small, although
abnormal, pressure gradient. When the mitral valve opening is reduced
to 1 cm2, which is considered to represent severe MS,[12] a  left
atrioventricular pressure gradient of approximately 20 mm Hg (and
therefore, in the presence of a normal LV diastolic pressure, a mean left
atrial pressure >25 mm Hg) is required to maintain normal cardiac
output at rest.
The elevated left atrial pressure raises pulmonary venous  and capillary
pressures, resulting in exertional dyspnea. The first bouts of
breathlessness in patients with MS are usually precipitated by
tachycardia resulting from exercise, pregnancy, hyperthyroidism,
anemia, infection, or AF.
8All these conditions (1) increase the rate of blood flow across the mitral
orifice, resulting in further elevation of the left atrial pressure, and (2)
decrease the diastolic filling time, resulting in a reduction in forward
cardiac output. Because diastole shortens proportionately more than
systole as heart rate increases, the time available for  mitral valve flow
is reduced at higher heart rates. Therefore, at any given stroke volume,
increase heart rate results in a higher instantaneous volume flow rate
and higher transmitral pressure gradient, which elevates left atrial
pressures further. This higher transmitral gradient, often in combination
with inadequate ventricular filling (because of the shortened diastolic
filling time), explains the sudden occurrence of dyspnea and pulmonary
congestion and  edema in previously asymptomatic patients with MS
who develop AF with a rapid ventricular rate.
9Elevated left atrial pressure results in pulmonary  venous and artery
hypertension, with secondary effects on the pulmonary vasculature and
right heart. In addition, left atrial enlargement and stasis of blood flow is
associated with an increased risk of thrombus formation particularly in
appendages and systemic embolism. Typically, the left ventricle is
usually normal, unless there is coexisting MR, with the primary
abnormalities of the left ventricle being a small underfilled chamber and
paradoxical septal motion caused by RV enlargement and dysfunction.
Mitral valve area is estimated by direct planimetry from two-
dimensional short-axis images and calculated by the Doppler pressure
half-time method. The transmitral gradient is  calculated  with use of
continuous wave Doppler and any coexisting Mitral regurgitation is
quantitated. Evaluation of the morphological status of the mitral valve is
important that  useful for predicting the hemodynamic status and
outcome of PTMC.
Hemodynamic Progression
Overall rate of progression was a decrease in valve area of 0.09 cm2/yr.
Approximately one third of patients  with mitral stenosis showed rapid
progression, defined as a decrease in valve area greater than 0.1 cm2/yr.
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Clinical Outcomes
 In the presurgical era  MS patients with symptoms have a poor clinical
outcome, with 5-year survival rates of 62% among patients with Mitral
stenosis in NYHA Class III but only 15% among those in Class IV. In
the surgical era  not operated patients still reported a 5-year survival rate
of  44% in patients with symptomatic MS who refused operation.
 Patients who underwent percutaneous or surgical  relief of valve
obstruction on the  current guidelines based therapy have great clinical
outcomes. However, longevity is  reduced compared with that expected
for age, mainly because of complications of the disease process  such as
AF, systemic embolism, pulmonary hypertension and side effects of
therapy such as  prosthetic valves, anticoagulation.
Echocardiography
MVO estimation by planimetry (Valve area (cm2))
Mild MS >1.5
Mod MS  1.0-1.5
Severe MS  <1.0
11
Image is recorded at the level of tip of mitral valve.
Mitral valve pressure gradient Estimation(Mean gradient (mm Hg))
Mild MS <5
Mod MS 5-10
Severe MS >10
Pulmonary Artery Systolic  pressure estimation
PASP estimated  from TR velocity using continuous wave doppler
PASP = 4 (Tricuspid regurgitant velocity)2 + RA pressure].
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PA Diastolic Pressure
PADP can be evaluated from the velocity of the end-diastolic PR jet
using the modified Bernoulli equation with CW doppler:
 [PADP = 4 (end-diastolic pulmonary regurgitant velocity)2 + RA
pressure].
Mean PA Pressure
Mean Pulmonary Artery pressure = 1/3(Systolic PAP)+ 2/3(PADP)
Mean Pulmonary Artery pressure = 79 - (0.45 x AT)
Patients with Acceleration time < 120 ms, the formula for
Mean PAP is= 90 - (0.62 x AT)
Mean PAP can also be estimated as 4 x(early PR velocity)2
+ estimated RA pressure.
Pulmonary Vascular Resistance
PVR = TR Velocity x 10/ RVOT  VTI + 0.16
Pulmonary Artery Diameter
Pulmonary artery dimension measured between Bifurcation point and
Pulmonary valve
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Echocardiographic scoring system divides patients into three
groups
Group 1-those with a pliable, noncalcified anterior leaflet and little
chordal disease
Group 2-  those with a pliable, noncalcified anterior leaflet but with
chordal thickening and shortening (<10 mm long;)
Group 3-  those with fluoroscopic evidence of calcification of any extent
of the valve apparatus.[13]
 Event-free survival at 3 years is highest for group 1 (89%) compared
with group 2 (78%) or group 3 (65%).[12,13]
In our study we used Wilkins echocardiographic scoring system.
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Wilkins Score
Excellent immediate and long-term results  with  score of 8 or less , but
scores higher than 8 are associated with less impressive results
including the complication  of new onset  of MR.
 Commissural calcification also is a predictor of poor outcomes
Estimation of the right atrial pressure
For Easy  estimation and uniformity of reporting, specific values of
Right Atrial pressure, rather than ranges,  used in the determination of
Systolic PAP.
IVC  diameter  less  than   2.1  cm  that  collapses  >50%  with  a  deep
inspiration suggests normal Right Atrial pressure of 3 mm Hg (range, 0-
15
5 mm Hg), whereas Inferior vena cava  diameter > 2.1 cm that collapses
< 50% with a deep inspiration suggests high Right Atrial pressure of 15
mm Hg (range, 10-20 mm Hg).
In situations in which Inferior Vena Cava diameter and collapse do not
fit this criteria, an intermediate value of 8 mm Hg (range, 5-10 mm Hg)
may be used or, preferably, other indices of Right Atrial  pressure
should be included to upgrade or downgrade to the normal or high
values of Right Atrial pressure.
Intermediate (8mmHg) RA pressures may be downgraded to normal
(3mmHg) if no secondary indicators of elevated RA pressure are
present, upgraded to high if minimal collapse with deep inspiration
(<35%) and secondary indices of elevated RA pressure are present, or
left at 8 mm Hg if uncertain.
In patients who are not able to adequately perform a deep inspiration ,
an IVC that collapses < 20% with quiet inspiration suggests elevated
Right Atrial  pressure.
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Estimation of RAP on the basis of IVC diameter and collapse
Variable Normal (0-5 [3]
mm Hg
Intermediate (5-
10 [8] mm Hg)
High (15 mm Hg)
IVC diameter <2.1 cm <2.1 cm  >2.1 cm
<50%         >50%
>2.1 cm
Collapse with
sniff
>50% <50%
Secondary
indicators of
elevated RAP
_ Restrictive filling
_ Tricuspid E/E0 > 6
_ Predominant
Diastolic flow in
hepatic
veins ( Filling
fraction in systole<
55%)
Measurement of the IVC.
The diameter  is estimated perpendicular to the long axis of the Inferior
Vena Cava at end-expiration, just proximal to the junction of the hepatic
veins that present roughly 0.5 to 3.0 cm proximal to the ostium of the
RA  During Deep inspiration,  IVC diameter is  measured.
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Management strategy for patients with mitral stenosis
Medical treatment
 Prevention of recurrent rheumatic fever.
 Prevention and treatment of complications of MS
Medical therapy with oral diuretics and the restriction of sodium intake
may improve symptoms .
Beta-blocking agents and  calcium antagonists may increase exercise
capacity by reducing heart rate in patients with sinus rhythm, especially
in patients with AF.
Advised to avoid occupations requiring strenuous exertion.
Anemia and infections should be treated promptly.
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Anticoagulant therapy is indicated for prevention of systemic embolism
in MS patients with AF.
Monitoring disease progression to allow intervention at the optimal time
point
Algorithm for Intervention
Interventional treatment
Percutaneous transvenous mitral commissurotomy
Percutaneous Balloon Mitral Valvotomy
Patients with mild and  moderate MS who are asymptomatic commonly
remain so for years. But, severe or symptomatic MS patients have poor
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long-term results if the stenosis is not relieved with interventional
treatment .
Percutaneous Balloon Mitral Valvotomy  is the choice of  procedure  for
the treatment of  Mitral Stenosis so that surgical treatment is now
reserved for patients who require treatment  and are not candidates for a
percutaneous intervention procedure.[13]
BMV is recommended for symptomatic patients with moderate to
severe MS and with favorable valve morphology, no or mild MR, and
no evidence of left atrial thrombus . Even mild symptomatic patients,
such as a subtle decrease in exercise tolerance, are an indication for
intervention because the procedure relieves symptoms and improves
long-term outcome with a low procedural risk. In addition, BMV is
recommended for asymptomatic patients with moderate to severe MS
when mitral valve obstruction has resulted in pulmonary artery
hypertension with a pulmonary systolic pressure greater than 50 mm Hg
at rest or 60 mm Hg with exercise.
Even when valve morphology is not suitable, BMV  is reasonable for
symptomatic patients who are at higher risk for surgical treatment,
including patients with restenosis after a previous Balloon Mitral
20
Valvotomy  or previous commissurotomy who are unsuitable for
surgery because of very high risk.
BMV also indicated in  very old  patients, patients with associated
severe IHD, patients in whom MS is complicated by renal, pulmonary,
or neoplastic disease, women of reproductive  age in whom MV
replacement is undesirable, and pregnant women with Mitral Stenosis.
Percutaneous BMV may be considered for patients with moderate to
severe MS and new-onset Atrial Fibrillation.
PTMC
Antegrade approach
With Inoue balIoon
With side by side two smaller (15- to 20-mm) balloons
With Accura balloon
Retrograde approach
Through Aortic valve
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 Improvement in valvular function due to  Commissural separation and
fracture of nodular calcium. In several studies reported with decrease of
the mitral Mean pressure gradient from 18 mmHg  to 6 mm Hg,
average 20%  increase in cardiac output, and an average increase of the
calculated MVO, from 1 to 2 cm2 .[13-14]
In younger patients results are  impressive when severe valvular
thickening or calcification is absent . Elevated pulmonary vascular
resistance declines rapidly. Mortality rate has ranged from 1% to 2%.
Complications include cardiac perforation  and cerebral emboli , each in
roughly 1% of patients, and the development of Mitral regurgitation
severe enough to require sugery in another 2%.
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Rigid thickened valves with extensive subvalvular fibrosis and
calcification lead to suboptimal results.
A prospective randomized trial in which patients with severe MS
,similar clinical outcomes with BMV and the open surgical technique
that were superior to the results of the closed surgical valvotomy. After
7 years of procedure , mitral valve area was equivalent in the BMV and
open surgical groups, both significantly greater than in the closed
valvotomy group.
Surgical treatment
Closed Mitral commissurotomy
Open mitral vlvotomy
Mitral Valve Replacement
Surgical intervention for mitral stenosis is recommended for patients
with severe Mitral Stenosis and  symptoms (NYHA Class III or IV)
when PTMC is not available, PTMC is contraindicated because of
persistent left atrial clot or moderate to severe MR, or when the calcified
valve and surgical risk is acceptable.[15] The most preferred surgical
approach is valve repair (open mitra valvotomy, with or without
additional procedures) whenever possible.
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APPROACH ADVANTAGES DISADVANTAGES
Closed surgical
valvotomy
Inexpensive
Relatively simple
Good  results in selected
patients
Good long-term outcome
No direct visualization of
valve, feasible with
flexible, noncalcified
valves.
Contraindicated if MR >
2+
Surgical procedure
Open surgical valvotomy Visualization of valve
allows directed valvotomy
Subsequent  annuloplasty
for MR is feasible
Best results with flexible,
noncalcified valves
Surgical procedure.
Valve replacement Feasible in all patients
regardless of any extent of
valve calcification or
severity of MR
Surgical procedure
Effect of loss of annular-
papillary muscle
continuity on LV function
Prosthetic valve
Chronic anticoagulation
Balloon mitral
valvotomy
Percutaneous approach
Local anesthesia
Good hemodynamic
results in selected patients
Good long-term outcome
No direct visualization of
valve
Only feasible with flexible
noncalcified valves
Contraindicated if MR >
2+
24
Review of studies
Pulmonary arterial systolic pressure
Abdenasser Drighil1 et al studied Immediate impact  pulmonary arterial
systolic pressure after  successful percutaneous mitral valve
commissurotomy. This study showed reduction of PASP from
46.4+32.1 to  29.1+13.4 mmHg after PTMC.In these patients MVO
increased from 0.91+0.29 to  1.86+0.43. Mean transmitral gradient
(mmHg)  decreased from  16.4+8. to 8 5+1.5 mmHg.
Ahmad Noor 4 et al studied Determinants of Decrease in Pulmonary
Hypertension Following PTMC. In this study PASP decreased from
60.12+17.9  mmHg to 33.4+11.9   (mmHg) P value  < 0.01*. In this
study,  PASP decreased by 29%.
 Fawzy et al2 study showed Systolic pulmonary artery pressure
reduction of PASP from 48.3±17.4  to  40±13.7  mmHg after PTMC.
 Pulmonary  artery mean  pressure
Kamal Saad Mansour  et al3 study showed Mean PAP  38.12 ±8.43
mmHg  before PTMC that decreased immediately after PT MC  to
mean value of 32.78 ±7.89 mmHg.
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Pulmonary vascular resistance
Kamal Saad Mansour  et al3 study showed ,PVR before PTMC mean
value of 2.25±0.66wu decreased to  mean value of 1.76±0.52wu after
PTMC.
Lung B, Vahanian A5: Echocardiography in the patient undergoing
catheter BMV: et al study showed reduction in Pulmonary vascular
resistance.
Pulmonary artery acceleration time
Kamal Saad Mansour3 et al study showed  Pulmonary artery
acceleration time before PTMC  with mean value of 83.78±16.87m.sec.
that  immediately after PTMC   increased to mean value of 94.42±15.76
m.sec.
MATERIALS AND METHODS
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MATERIALS AND METHODS
Study Population
A total of 35 patients were enrolled for the study from the patients who
presented to Cardiology Department Govt General Hospital from the
period 1st July 2013 to March 31st 2014.
5 patients were excluded as per exclusion criteria.
 The remaining 30 patients, who satisfied all the inclusion  criteria were
selected for the study . Written consent was obtained from all patients
participating in the study.
The control group consisted of 10  age-matched healthy persons who
ranged in age from 18 to 42 years (mean age 28 years). None had ECG
or echocardiographic evidence of structural or functional cardiovascular
disease.
Patients did not have  systemic hypertension, diabetes mellitus, more
than mild aortic regurgitation and/or aortic stenosis nor New York Heart
Association functional class IV symptoms.
Indications for PTMC were New York Heart class ?II, ?IV,
planimetered MVA < 1.5 cm2, mitral regurgitation ? 2+, suitable valve
27
morphology by Wilkins score, and absence of concomitant
cardiovascular disease requiring surgical correction.
All patients were subjected to a detailed Echocardiographic examination
as per proforma.
 Echocardiogram was done using Philips HD7XE Echocardiographic
machine.
Echocardiographic measurements
The following echocardiographic parameters were done.
MVO estimation
MVO estimation was done by planimetry using two dimensional short
axis view at the level of mitral valve tips.
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Mitral valve pressure gradient estimation
Mitral valve pressure gradient estimation was done with continuous
doppler.
Mitral regurgitation estimation
 Mitral regurgitation estimation by PISA method was done  before and
after PTMC.16
MR    Severity16
Grades Grade 1 Grade 2 Grade 3 Grade 4
Severity Mild Moderate Severe
Regurgitation
volume
< 30 ml 30 to 44 ml 45 to 59 ml > 60 ml
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Pulmonary Artery Systolic  pressure11
PASP estimation was done with Tricuspid regurgitant velocity with
following formula
PASP = 4 (Tricuspid regurgitant velocity)2 + RA pressure].
Mean Pulmonary Artery Pressure11
Mean Pulmonary artery Pressure is derived from Pulmonary artery
acceleration time with the following formula.
Mean PA pressure = 79 - (0.45 x AT)
Patients with Acceleration time < 120 ms, the formula for Mean
Pulmonary Artery pressure is= 90 - (0.62 x AT)
30
Pulmonary Artery Diastolic pressure11
Pulmonary Artery Diastolic pressure is estimated from PASP and Mean
Pulmonary artery Pressure with the  following formula.
PADP= 3Mean PAP- PASP/2
This formula derived from
Mean PAP= 1/3 rd  PASP + 2/3 rd PADP
Pulmonary Vascular Resistance11
 Pulmonary Vascular Resistance is calculated from the following
formula
PVR = TR Velocity x 10/ RVOT  VTI + 0.16
31
 Pulmonary artery acceleration time11
Pulmonary artery acceleration time is measured with pulse wave
Doppler. Pulse wave doppler cursor is positioned just beyond
pulmonary valve tips. The time taken from onset of systole to peak
velocity is measured.
Right atrial pressure estimation11
RAP is estimated from IVC.
IVC diameter less than  2.1 cm that collapses >50% with a deep
inspiration indicates normal RA pressure of 3 mm Hg (range, 0-5 mm
Hg), whereas Inferior Vena Cava  diameter > 2.1 cm that collapses <
32
50% with a deep inspiration indicates high RA pressure of 15 mm Hg
(range;10-20 mm Hg).
In situations in which Inferior Vena Cava diameter and collapse do not
fit this criteria, an intermediate value of 8 mm Hg (range; 5-10 mm Hg)
is  used.
Intermediate (8mmHg) RA pressures may be downgraded to normal
(3mmHg) if no secondary indicators of elevated RA pressure are
present, upgraded to high if minimal collapse with deep inspiration
(<35%) and secondary indicators of elevated RA pressure are present,
or left at 8 mm Hg if uncertain.
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In patients who are not able to adequately perform a deep inspiration ,
an IVC that collapses < 20% with quiet inspiration suggests elevated
Right Atrial  pressure.
Pulmonary Artery Diameter
Pulmonary artery dimension is measured between Bifurcation point and
Pulmonary valve
All measurements were made by a single observer  blinded to the
patient’s identity and to pre- and post-PTMC status within 48 hrs.
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Percutaneous mitral commissurotomy
In our study all patients underwent  PTMC by the antegrade transeptal
approach using an Accura balloon and a stepwise dilatation strategy.18
The nominal balloon diameter was decided according to the height of
the patient [i.e height (cm)/10 + 10 = balloon diameter].17
Echocardiography was done at the end of the procedure to assess for
perforation and to look for an atrial left-to-right shunt using color flow
Doppler. Successful PTMC  procedure was defined as post-
valvuloplasty valve area > 1.5 cm2 with no more than 2+ mitral
regurgitation.
FINANCIAL SUPPORT: nil.
CONFLICT OF INTEREST: nil.
STATISTICAL ANALYSIS
Data analysis was done with use of SPSS, version 17. Descriptive
statistics were used to calculate the frequency, median, mean, and
standard deviation. Paired Student’s t-test was used to determine the
significance of differences between the various parameters before and
after PTMC procedure. Unpaired Student’s t-test was used to determine
the differences between patients with MS and healthy subjects.
 RESULTS
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RESULTS
Age Distribution
In our study there were 4 patients in the age group of  <20 yrs, 16
patients between 21 to 30 yrs,9 patients between 31 to 40 yrs and only 1
patient over 40 yrs had participated.
Sex Distribution
In our study group out of  total 30 patients 25 were female patients and
5 were  male patients.
36
MVO estimation
In our study  out of total 30 patients 25 patients had severe MS and 5
patients had Moderate MS.
p VALUE Control
Groups
MEAN ?
SD
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ?
SD
p VALUE
MVO <0.0000001 3.98?0.617 0.86?0 .17 1.58?0.17 <0.0000001
In our study 30 patients were included and MVO estimation done before
and after  Percutaneous Transvenous Mitral  Commissurotomy within
48 hrs by planimetry  .  Before PTMC mean MVO area is 0.86 +_ 0.17
sq cm. After PTMC  mean MVO area is increased significantly to  1.58
+_   sq  cm.  After  PTMC   Mean  MVO was  increased  more  than  50%.
This is statistically significant.
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In our study control group had a mean MVO area is 3.98?0.617.  In
patients before PTMC mean MVO area is 0.86 ? 0.17 sq cm. MVO
between control group and patients before PTMC is statistically
significant.
Mean Gradient estimation
In our study before PTMC 28 patients were found to have > 10 mmHg,
2 patients had 5 to 10 mmHg but no patient have less than
5 mmHg. After PTMC mean gradient had reduced and only 4 patients
had  > 10 mmHg, 19 patients had 5 to 10 mmHg and 7 patients had less
than 5 mmHg.
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pVALUE CONTROL
Groups
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ?
SD
p VALUE
MITRAL
Mean
Gradient
<0.0000001 2.13? 0.78 14.3?2.81 7.07?2.47 <0.0000001
In our study 30 patients were included and Mean gradient  estimation
was done before and after within 48 hrs of Percutaneous Transvenous
Mitral  Commissurotomy by using continuous Doppler. Before PTMC
mean Mean gradient was 14.3 ? 2.81mmHg.But  after  PTMC   mean
gradient had decreased significantly to  7.07 ? 2.47. After PTMC   Mean
gradient  was decreased more than 50%. This is statistically significant.
In our study the control group had an average MG  is 2.13 ?  o.78.  In
patients before PTMC the average MG is 14.3 ?  2.8. Mean gradient
between control groups and patients before PTMC is statistically
significant.
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Pulmonary Artery  Systolic pressure
p VALUE Control
Groups
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ?
SD
p VALUE
PASP <0.0000001 29.3?2.49 61.9?11.4 45.24?8.59 0.0000001
In our study  Pulmonary Artery  Systolic pressure estimation was done
before  and after  Percutaneous Transvenous Mitral  Commissurotomy
by using TR velocity with  continuous Doppler . Before PTMC the
average  Pulmonary Artery  Systolic pressure was  61.9? 11.4 mmHg.
After PTMC  Pulmonary Artery  Systolic pressure was decreased
significantly to  45.24? 8.59 mmHg. After PTMC an average of 16.66
40
mmHg  Pulmonary Artery  Systolic pressure  was decreased. This is
statistically significant.
 In our study out of  total  30 patients, before PTMC  13 patients had
moderate PHT and 18 patients had severe PHT  but no patients with
mild PHT. After PTMC only 4 patients had severe PHT and 8 patients
had moderate PHT and significantly 18 patients had mild PHT.
In our study, control group the average Pulmonary artery systolic
pressure was found to be 29.3?2.49 mmHg .  In patients before PTMC
the average Pulmonary artery systolic  pressure  was found to be
61.9? 11.4 mmHg .The  average Pulmonary artery systolic  pressure
between control group and patients before PTMC is statistically
significant.
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Mean Pulmonary artery pressure
In our study Mean   Pulmonary Artery   pressure estimation was done
Before  and After  Percutaneous Transvenous Mitral  Commissurotomy
by using Pulmonary artery acceleration time by pulse wave Doppler.
p VALUE Control
Groups
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ?
SD
p VALUE
Mean
PAP
<0.0000001 17.08?2.86 33.24? 6.1 25.2? 6.4 0.000006023
Before PTMC the average  Mean PAP was found to be 33.24? 6.1
mmHg. After PTMC the Mean PAP had decreased significantly to  25.2
? 6.4mmHg. After PTMC, an average of 8.04 mmHg  Pulmonary Artery
Mean  pressure  had decreased. This is statistically significant.
In our study the control group had a mean Pulmonary artery pressure
17.08?2.86 mmHg .  In patients Before PTMC mean Pulmonary artery
pressure was 33.24? 6.1mmHg . Mean Pulmonary artery pressure
between control groups and patients before PTMC is statistically
significant.
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Pulmonary artery Diastolic pressure
In our study Pulmonary Artery  Diastolic  pressure  was derived from
Pulmonary artery systolic and mean pressure using the following
formula.
PADP =( 3Mean PAP – PASP)/2
p VALUE CONTROL
GROUPS
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ?
SD
p VALUE
PADP 0.00003839 10.97?3.97 19.2? 4.7 14.8? 3.9 0.0002171
Before PTMC the average  Pulmonary Artery  Diastolic  pressure was
found to be 19.2 ? 4.7  mmHg. After PTMC the Pulmonary Artery
Diastolic  pressure had decreased significantly to 14.8 ? 3.9  mmHg.
After PTMC an average of 4.4 mmHg  Pulmonary Artery  diastolic
pressure  had decreased. This is statistically significant.
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Pulmonary artery acceleration time
In our study Mean   Pulmonary Artery   acceleration time was  estimated
before  and after  Percutaneous Transvenous Mitral  Commissurotomy
by using pulse wave doppler.
p VALUE CONTROL
GROUPS
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ?
SD
p VALUE
PAAT <0.0000001 135.4 ? 8.8 92 ? 9.8 107?16.1 0.00005413
Before PTMC the average  Pulmonary Artery  acceleration time was
found to be 92 ? 9.8 msec . After PTMC the  Pulmonary Artery
acceleration time had increased significantly to 107 ? 16.1. After PTMC
an average of 15 msec Pulmonary artery acceleration time has
increased. This is statistically significant.
In our study control group had a mean Pulmonary artery acceleration
time of 135.4 ? 8.8  msec  .   In  patients  before  PTMC  the  mean
Pulmonary artery acceleration time was 92 ? 9.8 msec . Pulmonary
artery acceleration time  between control groups and patients before
PTMC is statistically significant.
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Pulmonary artery Diameter
p
VALUE
CONTROL
GROUPS
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ?
SD
p
VALUE
Pulmonary
artery
diameter
0.0002000 2.05? 0.19 2.81?0.39  2.45? 0.41 0.0009453
 Before PTMC the average  Pulmonary Artery  Diameter  was found to
be 2.81?0.39 cm. After PTMC  Pulmonary Artery Diameter is
decreased significantly to 2.45? 0.41 cm. After PTMC average 3.6 mm
Pulmonary artery Diameter is decreased. This is statistically significant.
In our study control group had a mean Pulmonary artery Diameter of
2.05? 0.19.  In patients before PTMC a mean Pulmonary artery
Diameter was 2.81?0.39 cm. Pulmonary artery Diameter  between
control groups and patients before PTMC is statistically significant.
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Pulmonary vascular Resistance
p VALUE CONTROL
GROUPS
BEFORE
PTMC
MEAN ?
SD
AFTER
PTMC
MEAN ? SD
p VALUE
Pulmonary
vascular
Resistance
0.000005112 1.45?0.30 2.19?0.31 1.70? 0.28 <0.00001
Before PTMC the average  Pulmonary  Artery vascular Resistance was
2.19 ? 0.31 woods unit. After PTMC the Pulmonary Artery vascular
Resistance had decreased significantly to 1.70? 0.28 woods unit . After
PTMC an average of 0.42 woods unit  Pulmonary artery vascular
Resistance had decreased. This is statistically significant.
In our study ,control group subjects the mean Pulmonary vascular
Resistance was 2.05? 0.19 woods unit.  In patients before PTMC mean
Pulmonary vascular Resistance was 2.45? 0.41 woods unit. PVR
between control groups and patients before PTMC is statistically
significant.
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Pulmonary artery parameters between Nil to mild MR and
Moderate  MR patients
NIL TO MILD MR              MODERATE MR
BEFORE
PTMC
AFTER
PTMC
p VALUE
BEFORE
PTMC
AFTER
PTMC
p
VALUE
 Average
PASP
61.34 44.16 0.0000001 60.46 61 0.54
Average
Mean PAP
32.83 24.17 0.000003 37 34.3 0.013
Average
PADP
18.8 14.05 0.00010 22.2 21.1 0.204
PVR 2.19 1.63 0.0000001 2.17 2.01 0.63
Patients with nil, trivial and mild MR who undergone PTMC, after the
PTMC the MR status remain the same , then there is found to have
significant reductions in PASP, Mean PAP,PADP,PVR. But in patients
have Nil, Mild  MR before PTMC if post PTMC they develop moderate
MR as a complication then there is no significant reduction in the
parameters of PASP, PADP and PVR.
DISCUSSION
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DISCUSSION
MVO Analysis
BEFORE PTMC
MEAN ? SD
AFTER PTMC
MEAN ? SD
p VALUE
MVO 0.86 ? 0 .17 1.58 ?  0.17 <0.0000001
In our study 30 patients were included and MVO estimation done before
and after  Percutaneous Transvenous Mitral  Commissurotomy within
48 hrs by planimetry  . Before PTMC mean MVO area is 0.86 ? 0.17 sq
cm. After PTMC  mean MVO area is increased significantly to  1.58 ?
sq cm. After PTMC   Mean MVO was increased more than 50%. This is
statistically significant.
Abdenasser Drighil1et al study showed MVO increased from 0.91?0.29
to  1.86?0.43.
Ahmad  Noor et 4 al study showed MVO increased from 0.88?0.13 cm2
to  1.79?0.28 cm2.
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Mean Gradient Analysis
BEFORE PTMC
MEAN ? SD
AFTER PTMC
MEAN ? SD
p VALUE
MITRAL
Mean
Gradient
14.3 ? 2.81 7.07 ? 2.47 <0.0000001
In our study 30 patients were included and Mean gradient  estimation
was done before and after within 48 hrs of Percutaneous Transvenous
Mitral  Commissurotomy by using continuous Doppler. Before PTMC
mean Mean gradient was 14.3 ? 2.81mmHg.But  after  PTMC   mean
gradient had decreased significantly to  7.07 ? 2.47. After PTMC   Mean
gradient  was decreased more than 50%. This is statistically significant.
Abdenasser Drighil1et al study showed Mean transmitral gradient
(mmHg)  decreased from  16.4?8. to 8. 5?1.5 mmHg.
Ahmad Noor et 4 al study showed Mean pressure gradient across mitral
valve decreased from 18.42?7.2 mmHg to  11.85?3.6 mmHg.
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Pulmonary Artery  Systolic pressure Analysis
BEFORE PTMC
MEAN ? SD
AFTER PTMC
MEAN ? SD
p VALUE
PASP 61.9? 11.4 45.24? 8.59 0.0000001
In our study  before PTMC the average  Pulmonary Artery  Systolic
pressure was  61.9? 11.4 mmHg. After PTMC  Pulmonary Artery
Systolic pressure was decreased significantly to  45.24? 8.59 mmHg.
After PTMC an average of 16.66 mmHg  Pulmonary Artery  Systolic
pressure  was decreased. This is statistically significant.
Abdenasser Drighil1et al study showed reduction of PASP from 46.4±
32.1 to  29.1± 13.4 mmHg after PTMC. An average of 17.3 mmHg
PASP had decreased. In these patients MVO increased from 0.91?0.29
to   1.86?0.43. Mean transmitral gradient (mmHg)  decreased from
16.4?8. to 8 5?1.5 mmHg.
In Ahmad Noor 4 et al study PASP decreased from 60.12?17.9  mmHg
to 33.4?11.9   (mmHg) p value  < 0.01.
Fawzy et al2 study showed Systolic pulmonary artery pressure reduction
from 48.3?17.4  to  40?13.7  mmHg after PTMC.
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Analysing with various studies our study also has similar reduction of
PASP after PTMC
In our study total  30 patients 13 patients have moderate PHT and 18
patients have severe PHT  and 0 patients in mild PHT Before PTMC  .
After PTMC only 4 patients have severe PHT and 8 patients have
moderate PHT and significantly 18 patients have mild PHT.
After successful PTMC patients with severe PHT become moderate
PHT, patients with moderate PHT become mild PHT.
Mean Pulmonary artery pressure Analysis
BEFORE PTMC
MEAN ? SD
AFTER PTMC
MEAN ? SD
p VALUE
Mean PAP 33.24? 6.1 25.2? 6.4 0.000006023
Before PTMC the average  Pulmonary Artery  Mean  pressure was
33.24? 6.1 mmHg. After PTMC the Pulmonary Artery  Mean pressure
had decreased significantly to  25.2? 6.4mmHg.  After  PTMC  an
average  of  8.04  mmHg   Pulmonary  Artery   Mean   pressure   had
decreased.
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Kamal Saad Mansour  et al3 study showed Mean PAP  38.12 ?8.43
mmHg  before PTMC that decreased immediately after PT MC  to a
mean value of 32.78 ?7.89 mmHg. After PTMC an average of 5.34
mmHg  Pulmonary Artery  Mean  pressure  had decreased.
Comparing with previous studies our study also showed higher
reduction of Mean PAP after PTMC.
Pulmonary artery Diastolic pressure Analysis
BEFORE PTMC
MEAN? SD
AFTER PTMC
MEAN ? SD
p VALUE
PADP 19.2 ? 4.7 14.8 ? 3.9 0.0002171
Before PTMC the average  Pulmonary Artery  Diastolic  pressure was
19.2 ?  4.7  mmHg. After PTMC the Pulmonary Artery  Diastolic
pressure had decreased significantly to 14.8?  3.9 mmHg. After PTMC
an average of 4.4 mmHg  Pulmonary Artery  diastolic  pressure  had
decreased.
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Pulmonary artery acceleration time Analysis
BEFORE PTMC
MEAN?  SD
AFTER PTMC
MEAN ?  SD
p VALUE
PAAT 92 ? 9.8 107 ?  16.1 0.00005413
Before PTMC the average  Pulmonary Artery  acceleration time was 92
? 9.8 msec . After PTMC the Pulmonary Artery  acceleration time had
increased significantly to 107 ? 16.1. After PTMC an average of 15
msec Pulmonary artery acceleration time has increased.
Kamal Saad Mansour3 et al study showed  Pulmonary artery
acceleration time before PTMC  with mean value of 83.78 ?
16.87m.sec. which  immediately after PTMC   increased to mean value
of 94.42? 15.76 m.sec. After PTMC an average of  10 msec Pulmonary
artery acceleration time had increased.
In our study results also comparable to previous studies.
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Pulmonary artery Diameter Analysis
BEFORE
PTMC MEAN
?  SD
AFTER PTMC
MEAN ?  SD
p VALUE
Pulmonary
artery diameter
2.81? 0.39 2.45?  0.41 0.0009453
Before PTMC the average  Pulmonary Artery  Diameter  was 2.81? 0.39
cm. After PTMC the Pulmonary Artery Diameter had decreased
significantly to 2.45?  0.412. After PTMC an average  of 3.6 mm
Pulmonary artery Diameter was decreased.
In Rheumatic MS because of PHT pulmonary artery diameter was
increased. After PTMC with reduction of PHT, pulmonary artery
diameter also reduced significantly.
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Pulmonary vascular Resistance Analysis
BEFORE
PTMC MEAN
?  SD
AFTER PTMC
MEAN ?  SD
p value
Pulmonary
vascular
Resistance
2.19 ?  0.31 1.70 ?  0.28 <0.0000001
Before PTMC the average  Pulmonary  Artery vascular Resistance was
2.19 ?  0.31woods unit. After PTMC the Pulmonary Artery vascular
Resistance had decreased significantly to 1.70?  0.28 . After PTMC an
average 0.42 woods unit  Pulmonary artery vascular Resistance had
decreased.
Kamal Saad Mansour 3 et al study showed that ,PVR before PTMC with
mean value of 2.25? 0.66 woods unit  decreased to  mean value of 1.76
? 0.52 wu after PTMC. After PTMC an average of  0.49 woods unit
Pulmonary artery vascular Resistance is decreased
Lung B, Vahanian A5: Echocardiography in the patient undergoing
catheter BMV: et al study showed reduction in Pulmonary vascular
resistance.
55
New onset of Moderate MR and Pulmonary artery Parameters
NIL TO MILD MR p value MODERATE MR p
value
BEFORE
PTMC
AFTER
PTMC
0.0000001 BEFORE
PTMC
AFTER
PTMC
Average
PASP
61.34 44.16 0.000003 60.46 61 0.54
Average
Mean
PAP
32.83 24.17 0.00010 37 34.3 0.013
Average
PADP
18.8 14.05 0.0000001 22.2 21.1 0.204
PVR 2.19 1.63 2.17 2.01 0.63
In our study patients initially presented with Nil and Trivial MR after
PTMC if patients develops mild MR a complication of PTMC, In spite
of  New onset of Mild MR these patients showed significant reduction
of  pulmonary artery parameters.
In our study patients presented  with nil, Trivial , Mild Mitral
regurgitation showed significant reduction of PASP ,Mean PAP, PADP
and PVR after successful  PTMC . But patients presented with Moderate
MR after PTMC as a complication of procedure that patients pulmonary
artery parameters does not reduced significantly in spite of successful
PTMC.
CONCLUSION
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CONCLUSION
1.PTMC is a safe and effective procedure in Rheumatic mitral stenosis.
After successful PTMC, pulmonary artery hemodynamics such as
PASP, Mean PAP,PADP, Pulmonary vascular resistance as well as
Pulmonary artery diameter was significantly reduced with in 48 hrs.
This is easily measured with simple non invasive echocardiographic
assessment.
2.With significant reduction of Pulmonary artery pressure after PTMC
the Pulmonary artery acceleration time was significantly increased.
3. If patient develop moderate MR following PTMC as a complication
of procedure ,Pulmonary artery hemodynamic parameters were not
significantly reduced with in immediate 48 hrs.
LIMITATIONS OF STUDY
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LIMITATIONS OF STUDY
1.This  study included  30 patients only.
2.This study focused only as the immediate impact of pulmonary artery
parameters after PTMC. The Long term outcome were  not evaluated.
3.We did not confirm with invasive Pulmonary artery hemodynamic
values .
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ACRONYMS
PTMC  -  Percutaneous Transvenous Mitral Commissurotomy
MVO - Mitral Valve Orifice
TR  - Tricuspid Regurgitation
NYHA -  New York Heart Association
PVR - Pulmonary vascular Resistance
PASP - Pulmonary Artery Systolic pressure
PADP - Pulmonary Artery Diastolic pressure
Mean PAP-  Mean Pulmonary Artery  pressure
MS- Mitral stenosis
RHD - Rheumatic Heart Disease
PHT- Pulmonary Hypertension
MR - Mitral Regurgitation
AT - Acceleration Time
MVA - Mitral Valve Area
ACRONYMS
IVC - Inferior Vena Cava
LV - Left Ventricle
RA - Right Atrium
BMV - Balloon Mitral Valvotomy
MG - Mean Gradient
AF - Atrial Fibrillation
RV - Right Ventricle
PROFORMA
Echocardiographic Assessment of
Pulmonary Artery Parameters Before and After PTMC in
Rheumatic Mitral Stenosis
Name Height
Age Weight
Sex
Address
Diagnosis
Balloon Size
Pre PTMC After PTMC
IMMEDIATE
M mode
Pulmonary artery Diameter
RVOT Diameter
A  wave
Mid systolic notching
Continuous Doppler
TR velocity
TR PG
Pulmonary Artery Systolic Pressure
Pul Regurgitation Peak Diastolic gradient
Pul Regurgitation End Diastolic gradient
Pul Regurgitation Diastolic pressure
Pul Regurgitation Mean Pressure
Pulse Doppler
Pulmonary Flow Acceleration time
Mid systolic notch
Right Atrial Pressure Estimation
IVC Diameter  End Expiratory
       Sniff Diameter
Pulmonary artery Resistance
TR velocity
RVOT VTI
PVR= TR velocity/ RVOT VTI x 10 + 0.16
Pulmonary Blood Flow
RVOT VTI
RVOT Diameter
Area
RV  Stroke Volume
Heart rate
Q p
Mitral stenosis
MVO (Planimetry)
Mean Gradient
Mitral Regurgitation
Associated Lesions
MASTER   CHART - STUDY GROUP
S.
NO
AGE SEX PASP
(B)
PASP
(A)
Mean
PAP (B)
Mean
PAP (A)
PADP
( B)
PADP
(A)
PVR
(B)
PVR
(A)
1 24 FEMALE 65 39 27.83 9.25 9 8.2 1.95 1.33
2 23 FEMALE 66.3 44.8 36.3 29.6 22.1 22 2.6 1.3
3 17 MALE 81 47.1 43.1 26 24.1 15.5 1.89 1.88
4 31 FEMALE 66.3 41.6 33 20.7 16.2 10.25 1.56 1.29
5 27 FEMALE 56 50 33.4 26.8 22.1 15.2 2.59 1.71
6 24 FEMALE 70.5 63.2 37.5 33.86 21 19.2 1.81 1.49
7 18 MALE 65.3 60 36.3 33.4 21.8 20.1 1.86 1.49
8 29 FEMALE 48.2 40.1 28.2 22.9 18.2 14.2 2.4 1.9
9 25 MALE 93 52 46.6 34.1 27.6 15.4 2.47 2.1
10 25 FEMALE 53 34 30.7 21 19.5 14.5 2.4 1.7
11 30 FEMALE 69 41.6 34 21 17.2 11.2 1.6 1.3
12 23 FEMALE 75 46 39 26 21 16 1.92 1.6
13 28 FEMALE 62.4 44.8 35.1 27.1 21.4 18.2 2.4 1.8
14 39 FEMALE 67 42 34 23 18 13 2.2 1.41
15 23 FEMALE 58 45 33 24.4 21.2 14.1 2.6 1.72
16 33 FEMALE 66 47.2 37.5 33.86 23 15.2 1.9 1.52
17 35 FEMALE 48.2 38.2 26.8 21.7 16.1 13.4 2.3 1.7
18 33 MALE 71 53 41 27.8 26 15.2 2.49 2.2
19 25 FEMALE 46 34 23.3 18.1 12 10.2 2.2 1.7
20 22 FEMALE 49 39 27.3 21.8 16.5 13.2 2.5 1.74
21 39 FEMALE 65.2 42.2 34.1 23.8 18.6 14.6 2.3 1.7
22 38 FEMALE 52 44 31.3 25.4 21 16.2 1.92 1.6
23 40 FEMALE 58 41 31.4 22.4 18.2 13.2 2.5 1.8
24 45 FEMALE 45.2 32.2 21.2 16.2 9.2 8.2 1.8 1.5
25 30 FEMALE 74 56.2 40 34.1 23 18.2 2.4 2.1
26 17 MALE 48 34 23.3 16.7 11 8 1.9 1.5
27 18 FEMALE 67 62 37 34.6 21.8 21 2.3 2.2
28 30 FEMALE 56 43 32.8 24.7 21.2 15.6 2.3 1.8
29 33 FEMALE 47 39 24.6 20.4 13.4 11.2 2.2 1.8
30 26 FEMALE 67 61 37.7 35.1 23 22.2 2.4 2.34
MASTER   CHART - STUDY GROUP
S.
NO
PAAT
(B)
PAAT
( A)
MVO
(B)
MVO
( A)
MG
(B)
MG
(A)
MR (B) MR(A) PA
DM (B)
PA
DM (A)
1 100 155 1.2 1.7 15 10 TRIVIAL MILD 2.54 2.6
2 87 97 0.6 1.2 13 8 TRIVIAL MILD TO
MODERATE
3.1 2.6
3 76 103 0.8 1.3 19 7.8 NIL TRIVIAL 2.8 2.21
4 92 112 1 1.8 13.3 8.6 MILD MILD 2.55 2.14
5 91 102 0.72 1.4 10 4.8 NIL MILD 3.6 3.2
6 85 91 0.72 1.55 18.5 8.4 MILD MILD 2.05 1.77
7 87 91 0.7 1.4 14 12 MILD MOD 2.3 1.87
8 100 108 0.9 1.5 12 6 NIL NIL 3.2 2.8
9 70 90 0.8 1.5 11 5 NIL NIL 3.4 3.2
10 96 111 0.8 1.6 15 6 NIL NIL 2.7 2.4
11 90 111 0.9 1.8 14 8.6 MILD MILD 2.6 2.3
12 82 103 0.9 1.5 19 7.8 NIL TRIVIAL 2.9 2.1
13 89 101 0.7 1.6 15 8 TRIVIAL MILD 3.1 2.8
14 90 108 1 1.7 17 9 TRIVIAL MILD 2.65 2.3
15 92 106 0.8 1.5 14 5.2 NIL NIL 3.4 3.1
16 85 91 0.7 1.6 17.2 8.6 NIL MILD 2.4 1.9
17 102 110 0.9 1.5 12 6 NIL NIL 3 2.7
18 79 100 0.8 1.6 14 4 NIL NIL 3.4 3.1
19 108 116 1.1 1.8 13 4 NIL MILD 3.2 2.6
20 101 110 1 1.6 11 3.8 NIL NIL 3.1 2.8
21 90 107 0.7 1.6 14 6 TRIVIAL MILD 2.8 2.2
22 95 104 0.8 1.4 14 8.2 NIL TRIVIAL 2.9 2.3
23 95 109 0.9 1.6 14.2 6.6 NIL NIL 2.5 2.5
24 111 119 1.2 1.9 9 4 NIL NIL 2.6 2.2
25 81 90 0.6 1.4 19 8 MILD MILD 2.2 1.9
26 108 158 1.1 1.9 11 4.3 NIL TRIVIAL 3 2.4
27 85 89 0.6 1.4 19 13 MILD MOD 2.3 2.2
28 92 105 0.8 1.5 15 5.2 NIL NIL 2.9 2.8
29 105 112 1.1 1.8 11 4.2 NIL TRIVIAL 2.7 2.7
30 84 89 0.9 1.7 15 11 MILD MOD 2.5 1.9
MASTER CHART -  CONTROL GROUP
S.
NO
AGE SEX PASP Mean
PAP
PADP PVR PAAT PA
DM
MG MVO
1 24 FEMALE 29 16 9.5 1.1 140 2.1 2.2 3.2
2 23 FEMALE 26 16.5 11.75 1.21 138 2.3 3.4 4.3
3 32 FEMALE 28 13.3 5.95 1.34 146 2 1.2 4.6
4 25 MALE 30 15.1 7.65 1.62 142 1.9 3.2 4.2
5 27 FEMALE 28 20.5 16.75 1.42 130 2.3 1.4 3.9
6 36 FEMALE 26 16.8 12.2 1.21 118 1.7 1.3 3.1
7 33 FEMALE 34 22.3 16.45 1.37 126 2.2 1.8 4.6
8 18 MALE 30 14.2 6.3 1.29 144 2.1 2.2 4.7
9 42 FEMALE 32 16.5 8.75 2.01 138 1.9 1.8 4
10 26 FEMALE 30 19.6 14.4 1.93 132 2 2.8 3.2
ETHICAL COMMITTEE APPROVAL ORDER
PLAGIARISM CERTIFICATE
PATIENT CONSENT FORM
Study	Details:		 Echocardiographic	 Assessment	 of	 Pulmonary	 Artery					
Parameters	Before	and	After	Successful	Percutaneous	
Transmitral	 Commissurotomy	 in	 	 Rheumatic	 Mitral	
Stenosis	
	
Study	Centre	:	 Department	of	Cardiology	
																																										Madras	Medical	College	and		
	 	 	 	Rajiv	Gandhi	Government	General	Hospital,		
	 	 	 	Chennai	-	600	003.	
Patient may check (?) these boxes:I	confirm	that	 I	have	understood	the	purpose	of	procedure	for	the	 above	 study.	 I	 have	 the	 opportunity	 to	 ask	 question	 and	 all	 my	questions	and	doubts	have	been	answered	to	my	complete	satisfaction.		 I	understand	that	my	participation	in	the	study	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time	without	giving	reason,	without	my	legal	rights	being	affected.		 I	 understand	 that	 the	 investigator	of	 the	 clinical	 study,	 others	working	 on	 his	 behalf,	 the	 ethical	 committee	 and	 the	 regulatory	authorities	will	not	need	my	permission	to	look	at	my	health	records,	both	in	respect	of	current	study	and	any	further	research	that	may	be	conducted	in	relation	to	it,	even	if	I	withdraw	from	the	study.	However,	I	understand	that	my	 identity	will	not	be	revealed	 in	any	 information	released	 to	 third	 parties	 or	 published,	 unless	 as	 required	 under	 the	law.	I	agree	not	to	restrict	the	use	of	any	data	or	results	that	arise	from	this	study.		 I	agree	to	take	part	 in	the	above	study	and	to	comply	with	the	instructions	 given	during	 the	 study	 and	 faithfully	 cooperate	with	 the	study	 team	and	 to	 immediately	 inform	 the	 study	 staff	 if	 I	 suffer	 from	any	 deterioration	 in	 my	 health	 or	 well	 being	 or	 any	 unexpected	 or	unusual	symptoms.	I	 hereby	 give	 permission	 to	 undergo	 complete	 clinical	examination	and	questionnaire.		 	I	hereby	consent	to	participate	in	this	study.			Signature	/	Thumb	impression:																																								Place:		 Date:		Patient	Name	and	Address:	 		Signature	of	Investigator:																																																				Place:											Date:	Study	(Investigator’s	Name:								
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